EDEN PRAIRIE, MINN. — March 3, 2026 — Leads & Copy — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has appointed David Wambeke as Chief Business Officer, effective March 1, 2026.
Wambeke will also lead NeuroOne’s drug delivery program and collaborate with the executive team to advance clinical development and commercialization strategies.
In conjunction with his appointment, Wambeke purchased 1,000,000 shares of NeuroOne’s common stock at $0.6704 per share, the closing price on February 27, 2026. NeuroOne intends to use the net proceeds to support clinical and product development, working capital, and general corporate purposes.
NeuroOne granted Wambeke an inducement stock option to purchase 500,000 shares of common stock under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan. The option, approved by the compensation committee, has an exercise price of $0.6704 per share, a 10-year term, and vests over four years.
Wambeke’s responsibilities include refining product requirements, expanding relationships with key opinion leaders, and engaging potential pharmaceutical partners to maximize the value of NeuroOne’s drug delivery platform. He will also oversee investor relations and support strategic business development initiatives.
NeuroOne CEO Dave Rosa said Wambeke’s public company experience, capital markets expertise, and ability to translate strategic vision into operational and clinical execution will be instrumental in sharpening messaging, deepening investor engagement, and advancing business development activities.
Wambeke most recently served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company’s lead biologic into preeclampsia. He previously spent 16 years at Craig-Hallum Capital Group in life sciences investment banking.
Wambeke said he is excited to join NeuroOne at a pivotal moment. He added that NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. He believes greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation.
NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The Company is engaged in research and development for drug delivery and spinal cord stimulation programs.
The shares sold to Wambeke have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
The stock option will vest over four years, with 25 percent of the shares underlying the option vesting on the one-year anniversary of the grant date, and the remaining shares vesting in equal quarterly installments over the remaining three years. The inducement grant is subject to the terms and conditions of an award agreement and the plan under which it was granted.
Caution: Federal law restricts the sale of this device to or on the order of a physician.
Source: NeuroOne Medical Technologies Corporation
